A recent study by the CDC revealed that Pepto Bismol, containing bismuth subsalicylate, did not show a significant difference in preventing diarrhea compared to a placebo. The study, involving 270 participants traveling to specific regions, found no significant difference in symptoms between those taking the medication and those taking a placebo. While bismuth subsalicylate is FDA-approved for various gastrointestinal issues, including diarrhea treatment, the study suggests further research is needed to determine its effectiveness in preventing diarrhea among travelers. Procter & Gamble provided the medication for the study, but did not partake in the procedures. (Cbsnews)
